株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

デジタル情勢:炎症性腸疾患 (IBD)

Digital Landscape: Inflammatory Bowel Disease

発行 GlobalData 商品コード 696560
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
デジタル情勢:炎症性腸疾患 (IBD) Digital Landscape: Inflammatory Bowel Disease
出版日: 2018年09月06日 ページ情報: 英文 159 Pages
概要

当レポートでは、軽度から中等度および中等度から重度のクローン病 (CD) と潰瘍性大腸炎 (UC) の病態修飾療法 (DMT) を支持する、米国とEUCAN (カナダとEU5ヶ国) の製薬企業によるデジタル活動について調査分析し、患者/HCP (医療機関) 向けのデジタル活動について、体系的な情報を提供しています。

エグゼクティブサマリー

最近の動向

情勢と分析

  • 米国:患者向けの活動
  • 米国:HCP向けの活動
  • EUCAN:患者向けの活動
  • EUCAN:HCP向けの活動

付録・調査手法

目次
Product Code: GDHC043SP

"Digital Landscape: Inflammatory Bowel Disease (IBD)", analyzes digital activities undertaken by pharma industry in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC).

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights:

  • US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen was the most active competitor in the branded and social media spaces in 2017. Branded activity also seen from pipeline and biosimilar competitors. No IBD-specific mobile apps detected from pharma. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.
  • US HCPs: Good support available for US HCPs in the IBD branded space, with Stelara and Humira activity detected from Janssen and AbbVie in 2017, respectively. Unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations; social media activity restricted to corporate accounts.
  • EUCAN Patients: Good brand support for patients in Germany, the UK, and Canada, with IBD-specific activity detected from Takeda and Janssen in 2017. No multi-country unbranded from biologics manufacturers with Ferring providing the only example. Unbranded support is strongest in Germany overall, with new sites launched by Janssen and Pfizer in 2017. Social media support is weak overall; EUCAN IBD patients have access to good mobile app offerings, however none detected in Italy.
  • EUCAN HCPs: The EUCAN HCP landscape is underdeveloped. Most branded activity limited to Germany or the UK with all new activity seen in the UK in 2017. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

Companies Mentioned: AbbVie, Janssen, Takeda, UCB, MSD / Merck, Pfizer, Roche / Genentech, Gilead, Allergan, Ferring, Shire, Salix, Dr. Falk Pharma, TillottsPharma, Warner Chilcott.

Scope:

  • This report analyzes digital activities undertaken by pharma in support of therapies for disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC).
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy:

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital IBD space, and can assist our pharma clients derive value in a number of ways -
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in IBD
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in IBD and beyond, and learn about key patient and physician online activities in IBD.

Table of Contents

  • Executive Summary

Recent Developments

  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology
Back to Top